148 related articles for article (PubMed ID: 30059430)
21. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ
J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147
[TBL] [Abstract][Full Text] [Related]
22. Investigation of receptor radionuclide therapy with
Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.
Gubbi S; Al-Jundi M; Del Rivero J; Jha A; Knue M; Zou J; Turkbey B; Carrasquillo JA; Lin E; Pacak K; Klubo-Gwiezdzinska J; Lin FI
Front Endocrinol (Lausanne); 2020; 11():587065. PubMed ID: 33551992
[TBL] [Abstract][Full Text] [Related]
24. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
[TBL] [Abstract][Full Text] [Related]
25. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
Acar E; Çapa Kaya G; Durak H
Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
[TBL] [Abstract][Full Text] [Related]
26. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
27. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
28. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427
[TBL] [Abstract][Full Text] [Related]
29. 177Lu-DOTATATE PRRT in Recurrent Skull-Base Phosphaturic Mesenchymal Tumor Causing Osteomalacia: A Potential Application of PRRT Beyond Neuroendocrine Tumors.
Basu S; Fargose P
J Nucl Med Technol; 2016 Dec; 44(4):248-250. PubMed ID: 27634982
[TBL] [Abstract][Full Text] [Related]
30. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?
Vaisman F; Rosado de Castro PH; Lopes FP; Kendler DB; Pessoa CH; Bulzico DA; de Carvalho Leal D; Vilhena B; Vaisman M; Carneiro M; Corbo R
Clin Nucl Med; 2015 Feb; 40(2):123-7. PubMed ID: 25546220
[TBL] [Abstract][Full Text] [Related]
31. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
32. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
Campennì A; Pignata SA; Baldari S
Endocrine; 2015 Nov; 50(2):516-8. PubMed ID: 25471282
[TBL] [Abstract][Full Text] [Related]
33. The use of (68)Ga DOTATATE PET/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma.
Novruzov F; Aliyev JA; Jaunmuktane Z; Bomanji JB; Kayani I
Clin Nucl Med; 2015 Jan; 40(1):47-9. PubMed ID: 25275413
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience.
Satapathy S; Mittal BR; Sood A; Verma R; Panda N
Nucl Med Commun; 2020 Jul; 41(7):629-635. PubMed ID: 32371670
[TBL] [Abstract][Full Text] [Related]
35. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
[TBL] [Abstract][Full Text] [Related]
36. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study.
Ballal S; Yadav MP; Damle NA; Sahoo RK; Bal C
Clin Nucl Med; 2017 Nov; 42(11):e457-e466. PubMed ID: 28872545
[TBL] [Abstract][Full Text] [Related]
37. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study.
Stokkel MP; Verkooijen RB; Bouwsma H; Smit JW
Nucl Med Commun; 2004 Jul; 25(7):683-90. PubMed ID: 15208495
[TBL] [Abstract][Full Text] [Related]
38. Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome.
Novruzov F; Mehmetbeyli L; Aliyev JA; Abbasov B; Mehdi E
Clin Nucl Med; 2019 Jun; 44(6):e415-e417. PubMed ID: 30789400
[TBL] [Abstract][Full Text] [Related]
39. PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.
Puranik AD; Dev ID; Rangarajan V; Kulkarni S; Shetty N; Gala K; Sahu A; Bhattacharya K; Dasgupta A; Chatterjee A; Gupta T; Sridhar E; Sahay A; Shetty P; Singh V; Moiyadi A; Menon N; Purandare NC; Agrawal A; Shah S; Choudhury S; Ghosh S; Jha AK
Neurol India; 2024 Mar; 72(2):278-284. PubMed ID: 38691470
[TBL] [Abstract][Full Text] [Related]
40. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
